Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F13A1 | P00488 | 1/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | TGM1 | P22735 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
| ▸ | MC5R | P33032 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL729259 | 0.91 | F13A1 (0.47) | F13A1TGM2TGM1SLC1A3SLC1A2 | |
| SCHEMBL16825184 | 0.84 | F13A1 (0.53) | F13A1TGM2TGM1MEN1KMT2A | |
| SCHEMBL20612386 | 0.82 | HPGD (0.55) | F13A1TGM2TGM1MEN1KMT2A | |
| SCHEMBL4681861 | 0.82 | SLC6A4 (0.51) | F13A1TGM2TGM1MEN1KMT2A | |
| SCHEMBL92054 | 0.81 | KMT2A (0.62) | MEN1KMT2ANPSR1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4682353 | 0.81 | SLC6A4 (0.50) | F13A1TGM2TGM1MEN1KMT2A | |
| SCHEMBL731880 | 0.81 | F13A1 (0.45) | F13A1TGM2TGM1SLC1A3SLC1A2 | |
| SCHEMBL731881 | 0.81 | F13A1 (0.45) | F13A1TGM2TGM1SLC1A3SLC1A2 | |
| SCHEMBL16464807 | 0.80 | F13A1 (0.52) | F13A1TGM2TGM1SLC1A3SLC1A2 | |
| SCHEMBL6406854 | 0.78 | SLC1A3 (0.50) | F13A1TGM2TGM1SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137184-B1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2013-05-08 | — | — | EP | disclosed |
| US-8138181-B2 | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100029633-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-02-04 | — | — | US | disclosed |
| EP-2137184-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008124323-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029633-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | PIM1, PIM3, PIM2 | F13A1 1765/4885TGM2 4536/4885TGM1 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.